Tachycardia induced Cardiomyopathy
Korean Circulation Journal
; : 808-817, 2019.
Article
em En
| WPRIM
| ID: wpr-917358
Biblioteca responsável:
WPRO
ABSTRACT
Recent studies on radiofrequency catheter ablation (RFCA) in atrial fibrillation show its effectiveness in heart failure (HF) patients; hence, tachycardia-induced cardiomyopathy (T-CMP) is gaining attention. Tachycardia-mediated cardiomyopathy is a reversible left ventricular (LV) dysfunction, which can be induced by any tachyarrhythmia. Early recognition of T-CMP with appropriate treatment of the arrhythmia culprit will lead to the recovery of LV function. Patients with tachycardia and LV dysfunction should be suspected of having T-CMP, with or without established etiology of HF, because T-CMP may present by itself or contribute as a co-existent component. Therapeutic options include rate control, anti-arrhythmic drugs, or catheter ablation. Unlike in animal models, clinical data on human T-CMP is limited. Hence, future research should be more focused on tachyarrhythmia-induced cardiomyopathy as its burden is increasing.
Texto completo:
1
Base de dados:
WPRIM
Idioma:
En
Revista:
Korean Circulation Journal
Ano de publicação:
2019
Tipo de documento:
Article